Galectin Therapeutics (GALT) Net Income towards Common Stockholders Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Galectin Therapeutics | 165.77 Mn | 151.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.38% |
| Dec 31, 2025 | 6.82% |
| Sep 30, 2025 | -6.67% |
| Jun 30, 2025 | -4.18% |
| Mar 31, 2025 | -22.03% |
| Dec 31, 2024 | -18.25% |
| Sep 30, 2024 | -31.86% |
| Jun 30, 2024 | -32.33% |
| Mar 31, 2024 | -4.80% |
| Dec 31, 2023 | -24.61% |
| Sep 30, 2023 | -35.75% |
| Jun 30, 2023 | -17.44% |
| Mar 31, 2023 | -20.47% |
| Dec 31, 2022 | -30.87% |
| Sep 30, 2022 | -12.98% |
| Jun 30, 2022 | -15.01% |
| Mar 31, 2022 | -13.74% |
| Dec 31, 2021 | -8.41% |
| Sep 30, 2021 | -13.00% |
| Jun 30, 2021 | -7.88% |
| Mar 31, 2021 | 1.99% |
| Dec 31, 2020 | -9.77% |
| Sep 30, 2020 | 0.65% |
| Jun 30, 2020 | -4.62% |
| Mar 31, 2020 | 6.89% |
| Dec 31, 2019 | -5.56% |
| Sep 30, 2019 | 6.06% |
| Jun 30, 2019 | 3.86% |
| Mar 31, 2019 | -10.95% |
| Dec 31, 2018 | -1.49% |
| Sep 30, 2018 | 3.93% |
| Jun 30, 2018 | 18.81% |
| Mar 31, 2018 | -5.52% |
| Dec 31, 2017 | -0.58% |
| Sep 30, 2017 | -9.33% |
| Jun 30, 2017 | -10.01% |
| Mar 31, 2017 | -18.77% |
| Dec 31, 2016 | -5.53% |
| Sep 30, 2016 | -14.71% |
| Jun 30, 2016 | -8.17% |
| Mar 31, 2016 | -20.83% |
| Dec 31, 2015 | -26.75% |
| Sep 30, 2015 | -26.50% |
| Jun 30, 2015 | -14.78% |